Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2018

View Archived Issues

Filoviruses hide out in sperm production site

Dogs and Duchenne

In rare encephalitis, neurons contribute to their own demise

XPO5 gene polymorphism found to protect from coronary artery disease risk

Kodiak completes enrollment in phase I study of KSI-301 in diabetic macular edema

TACI found to have prognostic value in heart failure

MedImmune patents new fusion proteins for heart failure

I-Mab Biopharma presents anti-CD73 antibodies for cancer

Janssen Pharmaceutica NV synthesizes 5-HT2B receptor antagonists

Immutep advances development of LAG-3 agonist antibody IMP-761

BenevolentAI Bio discloses orexin receptor antagonists

Phase I/IIa study of SYNB-1618 in healthy volunteers establishes dose for patients with PKU

ABX-464 shows promise in phase IIa trial in ulcerative colitis

Synthetic oligosaccharide conjugate vaccine for shigellosis evaluated in phase I trial

MHRA agrees in principle with proposed restart of Redx's phase I/IIa study of RXC-004

An epigenetic signature in non-small cell lung cancer predicts response to anti-PD-1 therapy

Jeil Pharmaceutical presents JP-1366, a potent potassium-competitive acid blocker for treating GERD

Janssen studies JNJ-67953964 in phase IIa for depression

IAVI enrolling healthy volunteers for first-in-human study of eOD-GT8 60mer vaccine, adjuvanted

Daiichi Sankyo studies DS-8201a in phase III trials for advanced HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...